CLYM vs ANL
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CLYM · Climb Bio$10.29 ▲ 16.01%
ANL · Adlai Nortye Group$10.28 ▲ 6.20%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CLYM +471.7%
- ANL +550.6%
Head to head
| Metric | CLYM | ANL |
|---|---|---|
| Price | $10.29 | $10.28 |
| Change today | ▲ 16.01% | ▲ 6.20% |
| Market cap | $604.42M | $662.01M |
| Return, 3 months | -24.0% | -22.3% |
| Return, year to date | +157.2% | +623.9% |
| Return, 1 year | +462.3% | +563.2% |
| P/E (TTM) | – | – |
| P/B | 2.7 | 3.1 |
| P/E percentile vs own 5y | 26th | 4th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -55.8% | -1,715.5% |
| Gross margin | – | – |
| Operating margin | – | -123.5% |
| Net margin | – | -124.8% |
| Return on equity | -27.1% | -20.2% |
| Analyst target vs. price | +177.9% | +199.6% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 48 | 40 |
| 30-day volatility | 90.4% | 95.1% |
| Max drawdown, 1 year | -50.6% | -45.7% |
| Trend read | Leaning bullish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ANL is the largest of the group by market value.
- ANL has returned the most over the past year.
- CLYM has been the calmest stock over the last 30 days.